US 11,692,045 B2
Method of treating inflammatory bowel disease (IBD), irritable bowel syndrome (IBS) or gluten hypersensitivity by administering an elastase 2A (ELA2A) inhibitor
Nathalie Vergnolle, Toulouse (FR); Corinne Rolland, Toulouse (FR); and Céline Deraison-Manuel, Toulouse (FR)
Assigned to Instutut Nationale de la Santé et de la Recherche Médicale, Paris (FR); Université Toulouse III—Paul Sabatier, Toulouse (FR); and Centre Nationale de la Recherche Scientifique (CNRS), Paris (FR)
Filed by INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Paris (FR); Université Toulouse III—Paul Sabatier, Toulouse (FR); and CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), Paris (FR)
Filed on Sep. 22, 2020, as Appl. No. 17/28,070.
Application 17/028,070 is a division of application No. 16/309,280, granted, now 10,829,563, previously published as PCT/EP2017/064786, filed on Jun. 16, 2017.
Claims priority of application No. 16305731 (EP), filed on Jun. 16, 2016.
Prior Publication US 2021/0040231 A1, Feb. 11, 2021
Int. Cl. C07K 16/40 (2006.01); C12N 15/113 (2010.01); C12N 15/115 (2010.01); C12Q 1/37 (2006.01); A61K 38/57 (2006.01); C12N 9/00 (2006.01); C12N 9/48 (2006.01); A61P 1/04 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 38/57 (2013.01); A61P 1/04 (2018.01); C12N 9/00 (2013.01); C12N 9/48 (2013.01); C12N 15/115 (2013.01); C12N 15/1137 (2013.01); C12Q 1/37 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01); C12N 2310/11 (2013.01); C12N 2310/12 (2013.01); C12N 2310/14 (2013.01); C12N 2310/16 (2013.01); G01N 2333/96433 (2013.01); G01N 2500/02 (2013.01); G01N 2500/10 (2013.01); G01N 2800/065 (2013.01)] 4 Claims
 
1. A method of treating Inflammatory Bowel Diseases (IBD), Irritable Bowel Syndrome (IBS) or gluten hypersensitivity in a patient in need thereof, comprising
administering to the patient a therapeutically effective amount of an elastase 2A (ELA2A) inhibitor,
wherein the ELA2A inhibitor is an anti-ELA2A neutralizing antibody, or
an aptamer, or
an inhibitor of ELA2A gene expression selected from a small inhibitory RNA (siRNA) and an antisense oligonucleotide.